Beam Therapeutics (BEAM) Projected to Post Earnings on Tuesday

Beam Therapeutics (NASDAQ:BEAM) is expected to be posting its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect Beam Therapeutics to post earnings of ($1.13) per share and revenue of $13.2150 million for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, March 3, 2026 at 7:00 AM ET.

Beam Therapeutics Trading Down 1.0%

Shares of BEAM stock opened at $27.59 on Monday. The company’s fifty day moving average price is $28.60 and its 200-day moving average price is $24.81. The stock has a market cap of $2.80 billion, a PE ratio of -6.23 and a beta of 2.12. Beam Therapeutics has a 12 month low of $13.52 and a 12 month high of $36.44.

Insider Activity

In other news, insider Christine Bellon sold 18,629 shares of the company’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $34.61, for a total transaction of $644,749.69. Following the transaction, the insider directly owned 97,038 shares of the company’s stock, valued at $3,358,485.18. This represents a 16.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 3.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Beam Therapeutics

Institutional investors have recently made changes to their positions in the business. Larson Financial Group LLC increased its holdings in Beam Therapeutics by 4,370.5% during the third quarter. Larson Financial Group LLC now owns 1,967 shares of the company’s stock valued at $48,000 after buying an additional 1,923 shares during the last quarter. Van ECK Associates Corp grew its position in shares of Beam Therapeutics by 48.7% during the 3rd quarter. Van ECK Associates Corp now owns 2,158 shares of the company’s stock valued at $52,000 after acquiring an additional 707 shares during the period. Kestra Advisory Services LLC purchased a new stake in shares of Beam Therapeutics in the 4th quarter worth $59,000. Daiwa Securities Group Inc. raised its holdings in Beam Therapeutics by 1,248.8% in the 2nd quarter. Daiwa Securities Group Inc. now owns 3,817 shares of the company’s stock worth $65,000 after purchasing an additional 3,534 shares during the period. Finally, IFC & Insurance Marketing Inc. purchased a new position in Beam Therapeutics during the fourth quarter valued at $69,000. Institutional investors own 99.68% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on BEAM shares. UBS Group started coverage on shares of Beam Therapeutics in a research note on Wednesday, January 7th. They set a “neutral” rating and a $28.00 price objective on the stock. Canaccord Genuity Group assumed coverage on Beam Therapeutics in a research report on Friday. They issued a “buy” rating and a $74.00 price target on the stock. Sanford C. Bernstein upped their price target on Beam Therapeutics from $37.00 to $41.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 20th. Evercore began coverage on Beam Therapeutics in a research report on Monday, November 24th. They set an “outperform” rating and a $35.00 price objective for the company. Finally, Benchmark reissued a “speculative buy” rating on shares of Beam Therapeutics in a report on Monday, November 17th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $45.69.

About Beam Therapeutics

Beam Therapeutics, Inc (NASDAQ: BEAM) is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need.

Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R.